Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective

Systemic treatment of renal cancer (RCC) has undergone remarkable changes over the past 20 years with the introduction of immunotherapeutic agents targeting programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) axis, as a single-agent or combined with anti-CTLA-4 monoclonal antibodies (MoAb...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Int J Mol Sci
Главные авторы: Lavacchi, Daniele, Pellegrini, Elisa, Palmieri, Valeria Emma, Doni, Laura, Mela, Marinella Micol, Di Maida, Fabrizio, Amedei, Amedeo, Pillozzi, Serena, Carini, Marco, Antonuzzo, Lorenzo
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2020
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7369721/
https://ncbi.nlm.nih.gov/pubmed/32630154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21134691
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы